Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 0

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1
Chunk 0
---
Overview

PetVivo
Holdings, Inc. (the “Company,” “PetVivo,” “we” or “us) is an emerging biomedical device company
focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals. The Company
has a pipeline of eighteen products for the treatment of animals and humans. A portfolio of twelve patents and six proprietary trade
secrets protects the Company’s biomaterials, products, production processes and methods of use. The Company began commercialization
of its lead product Spryng® with OsteoCushion® Technology, a veterinarian-administered, intraarticular
injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses, in the second quarter
of its fiscal year ended March 31, 2022.

In
August 2021, we received net proceeds of approximately $9.7 million in a registered public offering (“Public Offering”) of
2.5 million units at a public offering price of $4.50 per unit. Each unit consisted of one share of our common stock and one warrant
to purchase one share of our common stock at an exercise price of $5.625 per share. The shares of common stock and warrants were transferable
separately immediately upon issuance. In connection with the Public Offering, the Company’s common stock and warrants were registered
under Section 12(b) of the Exchange Act and began trading on The Nasdaq Capital Market, LLC under the symbols “PETV” and
“PETVW,” respectively.

The
Company was incorporated in March 2009 under Nevada law. The Company operates as one segment from its corporate headquarters in Edina,
Minnesota. For further information, see Note 1, Description of the Business, in the note to the consolidated financial statements
in Part II, Item 8.

Business
Description

The
Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage
afflictions of companion animals such as cats, dogs and horses. Most of our technology was developed for human biomedical applications,
and we intend to leverage the investments already expended in their development to commercialize treatments for horses and companion
animals in a capital and time-efficient way.

3

Many
of the Company’s products are derived from proprietary biomaterials that simulate a body’s cellular tissue by virtue of their
reliance upon natural protein and carbohydrate compositions